Enanta Pharmaceuticals, Inc. ENTA
8.69 USD -1.98 (-18.56%)
Regular-session close
8.99 +0.30 +3.45%
After hours · Nov 17, 7:29 PM ET
8.61 Day range 10.80
8.61 52-week range 17.15
- YTD
- -44.90%
- 1 year
- -32.22%
News
zacks.com Enanta Pharmaceuticals (ENTA) Reports Q4 Loss, Misses Revenue Estimates Enanta Pharmaceuticals (ENTA) came out with a quarterly loss of $0.81 per share versus the Zacks Consensus Estimate of a loss of $0.83. This compares to a loss of $0.87 per share a year ago.benzinga.com Enanta Pharma Q4 EPS $(0.81) Misses $(0.78) Estimate, Sales $12.868M Miss $14.200M Estimate Enanta Pharma (NASDAQ:ENTA) reported quarterly losses of $(0.81) per share which missed the analyst consensus estimate of $(0.78) by 3.85 percent. This is a 6.9 percent increase over losses of…
businesswire.com Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year-Ended September 30, 2026 WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological…
businesswire.com Enanta Pharmaceuticals to Participate in Upcoming Investor Conferences WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating novel, small molecule drugs for viral infections and…
businesswire.com Enanta Pharmaceuticals Announces Planned Retirement of Longstanding Chief Executive Officer Jay R. Luly, Ph.D. WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological…benzinga.com Enanta Pharmaceuticals Doses First Patient In Its RESOLVE Phase 2b/3 Clinical Trial Of Zelicapavir In Adults At High Risk Of Severe Outcomes From RSV; Topline Data Expected In 2027 The Phase 2b/3 randomized, double-blind, placebo-controlled, multicenter global trial will evaluate the efficacy and safety of zelicapavir in adult outpatients who test positive for RSV and have had…
businesswire.com Enanta Pharmaceuticals Announces First Patient Dosed in the RESOLVE Phase 2b/3 Study of Zelicapavir, a Potential First-in-Disease Treatment for Respiratory Syncytial Virus (RSV) WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological…
businesswire.com Enanta Pharmaceuticals to Present Data for Zelicapavir, an Oral, Once-Daily, N-Protein Inhibitor, in Development for the Treatment of Respiratory Syncytial Virus, at IDWeek™ 2026 WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical stage biotechnology company dedicated to creating novel, small molecule drugs for viral infections and…
defenseworld.net Comparing Enanta Pharmaceuticals (NASDAQ:ENTA) and Amphastar Pharmaceuticals (NASDAQ:AMPH) Amphastar Pharmaceuticals (NASDAQ: AMPH - Get Free Report) and Enanta Pharmaceuticals (NASDAQ: ENTA - Get Free Report) are both small-cap healthcare companies, but which is the better stock? We will…
defenseworld.net Bank of America Corp DE Reduces Stake in Enanta Pharmaceuticals, Inc. $ENTA Bank of America Corp DE cut its stake in Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA) by 59.7% in the first quarter, according to its most recent 13F filing with the Securities and Exchange…
gurufocus.com Enanta Pharmaceuticals to Participate in September Investor Conferences [url="]Enanta Pharmaceuticals, Inc.[/url] (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections
businesswire.com Enanta Pharmaceuticals to Participate in September Investor Conferences WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological…
zacks.com Enanta Pharmaceuticals (ENTA) Reports Q3 Loss, Lags Revenue Estimates Enanta Pharmaceuticals (ENTA) came out with a quarterly loss of $0.67 per share versus the Zacks Consensus Estimate of a loss of $0.37. This compares to a loss of $0.85 per share a year ago.
businesswire.com Enanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter Ended June 30, 2026 WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological…
zacks.com Enanta Pharmaceuticals (ENTA) Moves 5.2% Higher: Will This Strength Last? Enanta Pharmaceuticals (ENTA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in…
businesswire.com Enanta Pharmaceuticals' Partner AbbVie Receives European Commission Approval of MAVIRET® (Glecaprevir/Pibrentasvir) for People with Acute Hepatitis C Virus WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological…
businesswire.com Enanta Pharmaceuticals Announces Advancement of its Zelicapavir Clinical Development Program for the Treatment of Respiratory Syncytial Virus (RSV) WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological…
gurufocus.com Enanta Pharmaceuticals to Present at the Jefferies Global Healthcare Conference [url="]Enanta Pharmaceuticals, Inc.[/url] (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections
businesswire.com Enanta Pharmaceuticals to Present at the Jefferies Global Healthcare Conference WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological…
zacks.com Enanta Pharmaceuticals (ENTA) Reports Q2 Loss, Lags Revenue Estimates Enanta Pharmaceuticals (ENTA) came out with a quarterly loss of $0.45 per share versus the Zacks Consensus Estimate of a loss of $0.46. This compares to a loss of $1.06 per share a year ago.
businesswire.com Enanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter Ended March 31, 2026 WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological…
zacks.com Enanta Pharmaceuticals (ENTA) Moves 5.3% Higher: Will This Strength Last? Enanta Pharmaceuticals (ENTA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further…
